San Diego has been at the forefront of Alzheimer’s research, from the groundbreaking work of George Glenner at University of California, San Diego (UCSD) analyzing the beta amyloid protein linked to the disease, to the discovery at Sanford-Burnham of the last drug approved by the U.S. Food and Drug Administration (FDA) to treat it, to the leading-edge research being conducted today in San Diego County by world-renowned neuroscientists at the Scripps Research Institute, Salk Institute, UCSD, Sanford-Burnham Medical Research Institute, and others.
The Cure Roundtable, comprised of approximately 15 of the region’s preeminent Alzheimer’s disease and other dementia researchers, physician-scientists, biotech representatives and the San Diego County Medical Society, are focused on developing a collaborative regional strategy, integrating the work of researchers and San Diego’s unique drug discovery capabilities, and identifying funding strategies to support local research efforts.
Alzheimer’s San Diego, in partnership with the Salk Institute (Salk), Sanford-Burnham Medical Research Institute, the Scripps Research Institute (Scripps), UCSD, The J. Craig Venter Institute (Venter), Darlene Shiley, City and County of San Diego have launched the San Diego Dementia Drug Discovery Program called Collaboration 4 Cure (C4C). Collaboration 4 Cure is a San Diego-specific research fund to support local Alzheimer’s research projects in finding a cure for Alzheimer’s disease.
C4C is supported by funds raised through local philanthropic efforts with the goal of raising $7 million over the next five years.
You can help fund San Diego research and take an active role in the progress of finding a cure! All of the funds raised through C4C will go directly to San Diego research.
Encouraging community participation in clinical trials is another primary focal area for the Cure Roundtable.
In addition to investigating experimental drugs, many clinical trials in progress include various brain imaging studies and testing of blood or spinal fluid. Researchers hope these techniques will one day provide methods to diagnose Alzheimer's disease in its earliest, most treatable stages — possibly even before symptoms appear. Biomarkers may also eventually offer better methods to monitor response to treatment.
Approximately 50,000 volunteers, both with and without Alzheimer’s disease, are urgently needed to participate in more than 130 actively enrolling clinical trials about Alzheimer’s and other related dementias. Next to funding, recruiting and retaining trial participants, is a significant obstacle to developing the next generation of Alzheimer’s and other dementia treatments.